Published in J Mol Endocrinol on March 17, 2010
The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses. Am J Pathol (2011) 1.00
Cyclophilin B supports Myc and mutant p53-dependent survival of glioblastoma multiforme cells. Cancer Res (2013) 0.86
Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-Induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells. J Biol Chem (2016) 0.76
Retrospective Proteomic Screening of 100 Breast Cancer Tissues. Proteomes (2017) 0.75
Prolactin-mediated transcriptional and post-transcriptional control of casein gene expression. Cell (1979) 3.78
Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science (2007) 3.55
Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell (1999) 3.47
The role of prolactin in mammary carcinoma. Endocr Rev (2003) 2.95
A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol (2007) 2.80
Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay. Biochemistry (1991) 2.59
STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene (2006) 1.79
Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene (2005) 1.76
Isolation and sequencing of a cDNA clone for a prolactin-inducible protein (PIP). Regulation of PIP gene expression in the human breast cancer cell line, T-47D. J Biol Chem (1987) 1.76
Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A. Proc Natl Acad Sci U S A (2002) 1.71
STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat Immunol (2005) 1.57
Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J Virol (2007) 1.53
Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene (2003) 1.51
Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol (1995) 1.51
PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol Endocrinol (2002) 1.51
Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer (1997) 1.48
Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst (1999) 1.46
Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to Anoikis through inhibition of Bim. J Biol Chem (2006) 1.41
Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol Endocrinol (2006) 1.39
Prolyl isomerases and nuclear function. Cell (1998) 1.34
Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene (2002) 1.30
BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation. Oncogene (2003) 1.30
The mode of action of peptidyl prolyl cis/trans isomerases in vivo: binding vs. catalysis. FEBS Lett (1998) 1.29
Point mutations in v-Myb disrupt a cyclophilin-catalyzed negative regulatory mechanism. Mol Cell (1998) 1.28
CD147 is a signaling receptor for cyclophilin B. Biochem Biophys Res Commun (2001) 1.24
Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling. J Biol Chem (1999) 1.22
Emerging applications of network and pathway analysis in drug discovery and development. Curr Opin Drug Discov Devel (2008) 1.22
Syndecan-1/CD147 association is essential for cyclophilin B-induced activation of p44/42 mitogen-activated protein kinases and promotion of cell adhesion and chemotaxis. Glycobiology (2007) 1.21
Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter. BMC Biotechnol (2008) 1.21
The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proc Natl Acad Sci U S A (2002) 1.21
The role of prolactin and growth hormone in breast cancer. Oncogene (2000) 1.20
Prolactin as a chemoattractant for human breast carcinoma. Endocrinology (1999) 1.20
Overexpressed cyclophilin B suppresses apoptosis associated with ROS and Ca2+ homeostasis after ER stress. J Cell Sci (2008) 1.17
Posttranslational regulation of IRF-4 activity by the immunophilin FKBP52. Immunity (2000) 1.15
Cloning and characterization of a cDNA encoding a highly conserved, putative calcium binding protein, identified by an anti-prolactin receptor antiserum. J Biol Chem (1988) 1.14
Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Mod Pathol (2008) 1.13
Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology (1997) 1.12
Requirement of nuclear prolactin for interleukin-2--stimulated proliferation of T lymphocytes. Science (1991) 1.11
Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. Int J Cancer (2007) 1.11
Bcl3, an IkappaB protein, stimulates activating protein-1 transactivation and cellular proliferation. J Biol Chem (1999) 1.10
Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells. Oncogene (2004) 1.07
Prolactin signals via Stat5 and Oct-1 to the proximal cyclin D1 promoter. Mol Cell Endocrinol (2005) 1.06
Role of cyclophilin B in prolactin signal transduction and nuclear retrotranslocation. Mol Endocrinol (2000) 1.05
Calcyclin (S100A6) regulates pulmonary fibroblast proliferation, morphology, and cytoskeletal organization in vitro. J Cell Biochem (2003) 1.04
Transcriptional regulation of the generic promoter III of the rat prolactin receptor gene by C/EBPbeta and Sp1. J Biol Chem (1998) 1.02
Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells. Oncogene (2007) 1.01
Reassessing the role of C-MYB in tumorigenesis. Oncogene (1999) 1.01
Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer. Am J Pathol (2008) 1.00
Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. Cancer Res (2008) 0.99
Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia (1997) 0.97
Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice. J Endocrinol (2006) 0.97
Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene (2002) 0.95
Prolactin enhances CCAAT enhancer-binding protein-beta (C/EBP beta) and peroxisome proliferator-activated receptor gamma (PPAR gamma) messenger RNA expression and stimulates adipogenic conversion of NIH-3T3 cells. Mol Endocrinol (2000) 0.95
Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells. Endocrinology (2008) 0.94
The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis. Br J Cancer (1999) 0.91
From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J Mammary Gland Biol Neoplasia (2008) 0.91
The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells. Exp Cell Res (2008) 0.91
Cyclophilin B induces integrin-mediated cell adhesion by a mechanism involving CD98-dependent activation of protein kinase C-delta and p44/42 mitogen-activated protein kinases. Exp Cell Res (2007) 0.88
Expression cloning and characterization of PREB (prolactin regulatory element binding), a novel WD motif DNA-binding protein with a capacity to regulate prolactin promoter activity. Mol Endocrinol (1999) 0.85
Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev (2010) 2.09
Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol Endocrinol (2006) 1.39
Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter. BMC Biotechnol (2008) 1.21
The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proc Natl Acad Sci U S A (2002) 1.21
Intermittent hypoxia-induced changes in tumor-associated macrophages and tumor malignancy in a mouse model of sleep apnea. Am J Respir Crit Care Med (2014) 1.20
Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Mod Pathol (2008) 1.13
New mechanisms for PRLr action in breast cancer. Trends Endocrinol Metab (2009) 1.08
Fragmented sleep accelerates tumor growth and progression through recruitment of tumor-associated macrophages and TLR4 signaling. Cancer Res (2014) 1.05
Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer. Am J Pathol (2008) 1.00
Toxoplasma gondii actively remodels the microtubule network in host cells. Microbes Infect (2008) 0.99
Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. Cancer Res (2008) 0.99
Prolactin stimulates ubiquitination, initial internalization, and degradation of its receptor via catalytic activation of Janus kinase 2. J Endocrinol (2008) 0.98
The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry (2007) 0.97
Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor. Mol Endocrinol (2004) 0.96
Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells. Endocrinology (2008) 0.94
Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry. J Bioanal Biomed (2012) 0.94
From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J Mammary Gland Biol Neoplasia (2008) 0.91
The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells. Exp Cell Res (2008) 0.91
Characterization of a novel and functional human prolactin receptor isoform (deltaS1PRLr) containing only one extracellular fibronectin-like domain. Mol Endocrinol (2002) 0.90
Negative cross talk between NFAT1 and Stat5 signaling in breast cancer. Mol Endocrinol (2011) 0.88
Energy balance, early life body size, and plasma prolactin levels in postmenopausal women. Cancer Causes Control (2008) 0.87
Antiplatelet and antithrombotic activity of L-3-n-butylphthalide in rats. J Cardiovasc Pharmacol (2004) 0.86
HMGN2 inducibly binds a novel transactivation domain in nuclear PRLr to coordinate Stat5a-mediated transcription. Mol Endocrinol (2011) 0.83
The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer. Am J Pathol (2012) 0.82
Prolactin receptor-integrin cross-talk mediated by SIRPα in breast cancer cells. Mol Cancer Res (2010) 0.82
A humanized pattern of aromatase expression is associated with mammary hyperplasia in mice. Endocrinology (2012) 0.82
Comment on "Progesterone/RANKL is a major regulatory axis in the human breast". Sci Transl Med (2013) 0.81
Hormonal determinants of nipple aspirate fluid yield among breast cancer cases and screening controls. Cancer Epidemiol Biomarkers Prev (2013) 0.80
Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells. Mol Pharmacol (2012) 0.79
A novel and functional interaction between cyclophilin A and prolactin receptor. Endocrine (2003) 0.79
Antipsychotic treatment in breast cancer patients. Am J Psychiatry (2014) 0.76
Immunoassay and Nb2 lymphoma bioassay prolactin levels and mammographic density in premenopausal and postmenopausal women the Nurses' Health Studies. Breast Cancer Res Treat (2014) 0.76